

## **Dietitian Referral criteria**

Criteria	Y/N or Value	Doc. In Pics, Medical Notes, Both or Neither	Warrants referral	Referred to Dietitian (incl date)			
Anthropometry (most recent within 12 month period)							
Weight (kg)							
Weight loss of >5% in 3/12 (5)			Y				
Weight gain % (calculated to equivalent of 3 months)							
Height (m)							
Visible wasting; Body Mass Index BMI <20kg/m <sup>2 (7)</sup>			Y				
$BMI > 30 kg/m^2$			Y				
Waist Circumference (>88 women, >102 men) (4)			Υ				
Any other anthropometric notes							
Biochemistry (most recent values within 12 month period)							
CD4<200							
Viral load <50 copies/ml							
↑PTH (normal=1.1-6.8 pmol/L) (2)*							
↑ALP (normal= 30-130 U/L) (2)							
Fasting glucose mmol/l							
Total Cholesterol >5 mmol/l							
LDL >3 mmol/l							
Non-HDL >4 mmol/l							
TG >1.7 mmol/l							
HDL <1.3 mmol/l (women) HDL <1.0 mmol/l (men)							
TC:HDL >6 mmol/l							
Clinical							
Is patient on HAART medication?							
Anaemia present; indicate evidence*			Υ				
Evidence of body fat redistribution?							
Osteoperosis/ osteopenia present; indicate evidence*			Υ				
Dyslipidaemia present; indicate evidence*			Υ				
Persistent diarrhoea > 2 weeks			Υ				
Persistent constipation > 2 weeks			Υ				
Other GI complaints > 2 weeks (i.e.nausea, vomiting, IBS)			Υ				
Diabetes/uncontrolled blood glucose/ IFG, IGT			Υ				
Hypertension BP>140/90			Y				
Cardiovascular Risk Assessment: (Risk >20%)			Y				
Other clinical condition: liver, renal, heart disease, cancer							
Antenatal patient: need for nutrition education			Y				
Any other clinical notes							
Dietary							
Inadequate dietary intake (poor appetite, altered taste etc)			Υ				
Hypervitaminosis or excessive supplementation intake							
Pt taking oral nutritional supplements			Y				
Pt taking micronutrient supplements							
Any other dietary parameter: IBS/ Food allergies			?				
Any other dietary notes		•	•				

Any other inform	ation pertiner	nt at time o	t capture

NICE 2010 Obesity guidelines suggest that the level of intervention to discuss with the patient initially should be based as follows.

<sup>\*</sup> Evidence; medications



BMI	Waist circumference			Comorbidities
classification	Low	High	Very high	present
Overweight				
Obesity I				
Obesity II				
Obesity III				

General advice on healthy weight and lifestyle
Diet and physical activity
Diet and physical activity; consider drugs
Diet and physical activity; consider drugs; consider surgery

## **EACS**

Diet, exercise and maintaining normal body weight tends to reduce dyslipidaemia; if not effective, consider change of ART and then consider lipid-lowering medication in high-risk patients

Lipohypertrophy

Prevention

- No proven strategy
  Weight gain expected with effective ART
  Weight reduction or avoidance of weight gain may decrease visceral adiposity

- Diet and exercise may reduce visceral adiposity;
  Limited data, but possibly reduction of visceral adipose tissue and improvement in insulin sensivity and blood lipids, especially in obesity associated with lipohyperthrophy
- No prospective trials in HIVinfected patients to definitely indicate degree of diet and/or exercise needed to maintain reduction in visceral fat.

		Blood p	oressure (mmHg) - levels	+ diagnosis & grading of hyperten	sion
Other risk factors and disease history	Normal: SBP 120-129 or DBP 80-84	High normal: SBP 130-139 or DBP 85-89	Grade 1: SBP140-159 or DBP 90-99	Grade 2: SBP 160-179 or DBP100-109	Grade 3: SBP > 180 or DBP > 110
No other risk factors	Average risk	Average risk	Low added risk	Moderate added risk	High added risk
	No BP Intervention	No BP Intervention	Lifestyle changes for several months <sup>1</sup> , then possible drug therapy <sup>11</sup>	Lifestyle changes for several months <sup>1</sup> , then drug therapy <sup>4</sup>	Immediate drug therapy <sup>a</sup> and lifestyle changes <sup>a</sup>
1-2 risk factors*	Low added risk	Low added risk	Moderate added risk	Moderate added risk	Very high added risk
	Lifestyle changes	Lifestyle changes	Lifestyle changes for several months, then drug therapy	Lifestyle changes for several months <sup>1</sup> , then drug therapy <sup>4</sup>	Immediate drug therapy and lifesty changes
3 or more risk factors* or target organ disease* or diabetes	Moderate added risk	High added risk	High added risk	High added risk	Very high added risk
	Lifestyle changes	Drug therapy" and lifestyle changes"	Drug therapy" and lifestyle changes"	Drug therapy and lifestyle changes	Immediate drug therapy" and lifestyle changes
Associated clinical conditions <sup>ri</sup>	High added risk	Very high added risk	Very high added risk	Very high added risk	Very high added risk
	Drug therapy" and lifestyle changes"	Immediate drug therapy" and lifestyle changes"	Immediate drug therapy" and lifestyle changes"	Immediate drug therapy" and lifestyle changes"	Immediate drug therapy" and lifestyle changes*



## Literature References

- 1. European AIDS Clinical Society (2009), Guidelines: Prevention and Management of Non-Infectious Co-Morbidities in HIV.
- 2. Hobson, H (2008) St Mary's Hospital Pathology User Guide, Version 5.7
- 3. Nerad J, Romeyn M, Silverman E, len-Reid J, Dieterich D, Merchant J, et al. (2003) General nutrition management in patients infected with human immunodeficiency virus. *Clin Infect Dis*; **36**(Suppl 2):S52-S62.
- 4. NHS Choices, why is my waist size important (2010) [online] available at: http://www.nhs.uk/chq/Pages/849.aspx?CategoryID=51&SubCategoryID=165 [Accessed 07/01/11]
- 5. Ockenga *et al*, (2006) ESPEN guidelines on enteral nutrition: Wasting in HIV and other chronic infectious diseases
- 6. Polsky B, Kotler D, Steinhart C (2001) HIV-associated wasting in the HAART era: Guidelines for assessment, diagnosis and treatment, *AIDS patient care and STDs*, Vol **15**:8 pp.411- 423
- 7. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C (2005) Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-Infected patients, 1995 to 2003, Epidemiology and Social Science, *Journal of Acquired Immune Deficiency Syndrome*, Vol **40**:1 pp 70-76